NewsTrending topic
ANKTIVA and IL-15 Immunotherapy: What's Approved, What's Still Being Studied
ANKTIVA is an IL-15 immunotherapy that the FDA has approved for certain bladder cancers. Here is what it is, what it is approved for, and what is still being researched.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
A social media clip about ANKTIVA, which we could no longer confirm, prompted this page. ANKTIVA is an immunotherapy built around interleukin-15, or IL-15. IL-15 is a molecule. It helps turn on natural killer (NK) cells and other immune cells. These cells spot abnormal cells in the body.
Update, October 19, 2026: On October 14, 2026, the FDA widened the approval. It now also covers adults with a second type of bladder cancer that stopped responding to BCG. See what the expansion covers. The text below describes the original 2024 approval.
What's actually approved
ANKTIVA (nogapendekin alfa inbakicept) is a real, FDA-approved immunotherapy. When this page was first written, it was cleared for one specific form of bladder cancer: BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Doctors use it with BCG (Bacillus Calmette-Guérin) therapy, an older bladder cancer immunotherapy. It's for patients whose cancer didn't respond to BCG alone. An approval in another country does not mean the same approval exists in the US. Regulators in different countries can reach different decisions.
What's still being researched
Researchers are still studying IL-15 treatments for other cancers. It is not an approved treatment for other cancer types, and it is not a universal cancer cure. More evidence is needed.
What to do with this information
Do you or someone you know have bladder cancer that hasn't responded to standard BCG treatment? If so, ANKTIVA is an FDA-approved option for certain types of this cancer. It's worth asking a urologic oncologist about. For other cancer types, IL-15 immunotherapy is still just being studied. Check any claims about it against your own care team or a clinical trial listing, not social media.
How this article was prepared
An AI-assisted editorial system helped prepare this page based on public FDA approval announcements for ANKTIVA. No named medical reviewer has reviewed it unless one is listed.
Cancer Explained is published by the National Cancer Information Foundation. It is not medical advice and does not suggest a test or treatment.
See an error, old source, or unclear wording? Tell us.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Bladder cancer. The information below is general, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn more about bladder cancer
A news story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.